⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RYTM News
Rhythm Pharmaceuticals, Inc. Common Stock
Form 8-K
sec.gov
RYTM
Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026
globenewswire.com
RYTM
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
globenewswire.com
RYTM
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
globenewswire.com
RYTM
Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
globenewswire.com
RYTM
Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics
globenewswire.com
RYTM
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
globenewswire.com
RYTM
Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology
globenewswire.com
RYTM
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference
globenewswire.com
RYTM
Form 8-K
sec.gov
RYTM